Abstract :
Background: Pseudomonas aeruginosa is an important opportunistic pathogen that causes high risk in chronic kidney disease (CKD) patients due to their compromise condition.Aim and Objectives: This study aims to isolate of P. aeruginosa from CKD patients, study the incidence of OPRL, toxA, and exoS genes among clinical isolates using PCR technique, and to study the antibiotic resistance pattern among pathogenic bacteria.Materials and Methods: A total of 85 P. aeruginosa from various clinical samples of CKD patients were collected. Bacterial identity was confirmed applying of traditional methods and PCR amplification of the OPRL gene. The virulence gene detection was performed using Multiplex PCR targeting of toxA and exoS genes. Accordance with the CLSI guidelines the antimicrobial sensitivity tested was done.Results: All 85 isolates (100%) were positive for the OPRL gene, confirming their identity as P. aeruginosa. The prevalence of virulence genes was: toxA 78.8% (67/85) whereas exoS 64.7% (55/85). Co-occurrence of both toxA and exoS genes was observed in 52.9% (45/85) of isolates. Isolates harboring both virulence genes demonstrated significantly higher antibiotic resistance rates comparing to those with single or no virulence genes (p < 0>50 to ?70 years. Of the 1505 patients with recorded gender, 57.7% were male. The UTIs were diagnosed in 90.9% of cases. The predominant isolates were Escherichia coli (iib to Ceftriaxone/Sulbactam/EDTA (CSE) nwas highest (83.4%), while Meropenem, Imipenem, and Piperacillin/Tazobactam (TZP) showed lower susceptibility rates (65.8%, 63.6% and 48.3%, respectively). Among isolates non-susceptible to Meropenem and Imipenem, CSE showed susceptibility rates of 75.1 and 76.5 %, respectively.Conclusion: The UTIs were the most common diagnosis, with E. coli being the predominant pathogen. The findings underscore the higher susceptibility to CSE and rising non-susceptibility to Meropenem, Imipenem, and TZP, underscoring the concerning resistance level among bacterial isolates.
Keyword :
In-vitro, urinary tract infection, Escherichia coli, Ceftriaxone/Sulbactam/EDTA, Meropenem non-susceptible.